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CHAPTER 1. INTRODUCTION 
 
 In the current century, the development of medicine and molecular 
biotechnology has led to successful containment and even eradication of some human 
pathogens, especially in the developed countries. However, some pathogens have evolved 
resulting to the emergence of infectious diseases which also occur in the developed 
countries. The distribution of human pathogens basically affected by ecological factors 
such as wildlife biodiversity, climate, changes of local ecosystem, and human 
socioeconomic activities such as population density and growth, urbanization, use of 
antibiotic, and agricultural practices. Human socioeconomic activities together with the 
advancement of technology and transportation has led to quick movement of humans to 
different parts of the world. There is a great concern that this movement enhance the 
distribution of pathogens making it difficult to contain; as witnessed with the global 
spread of 2009 influenza pandemic within only 3 months (L`Vov et al., 2010), and 2014 
Ebola outbreak which spread in various west African countries within 8 months (Holmes 
et. Al., 2016). 
 
Among bacteria, fungi, protozoa and helminthes known to infect human, viruses 
especially RNA viruses, pose major threat to global health (Jones et al., 2008). Virus 
infection account for a third of emerging and re-emerging infections (Howard and 
Fletcher, 2012) and this has shifted the parasitic infection. Studies from 1912 to 2013 
reported that the shift from parasitic to viral infections is related to zoonosis (Wiethoelther 
et al., 2015) which indicate the importance of wildlife biodiversity and human 
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socioeconomic activity in virus distribution. To understand the viral infection, researchers 
are focusing on three key factors: first, is how the ecology, environmental changes, human 
societal pressures relate with viral diseases; second, is how the viruses can be transmitted 
to human and why it cause diseases; and third, is how to treat and prevent viral diseases.  
 
In case of how to treat and prevent viral diseases, many cases show that it is not 
always easy to apply specific medicine to treat viral infection because viruses easily adapt 
to human host as noted in case of human immunodeficiency virus (HIV). Drug discovery 
against HIV successfully achieved the highly active antiretroviral therapy. Thus, 
nowadays HIV infected patient can control the infection without progressing to acquired 
immunodeficiency disease syndrome (AIDS) as long they keep taking the medicine. 
However, it should be noted that only less than 5% of infected people can continuously 
take the medicine due to the high cost of medicine. In addition, the discovery of antiviral 
drugs is limited thus, the development of drugs against most of viral infections is still 
needed. Currently researchers are focusing on continuous drug development using 
combinatorial chemistry and medicinal plant approaches. In the past decade, combination 
of bioinformatics and medicinal chemistry has facilitated synthetic compounds as 
potential source for drug discovery. However, this strategy is facing a great challenge 
largely due to increased cost of production and reduction of approved drug because of 
poor absorption, distribution, metabolism, excretion or high toxicity (Ganesan, 2008). On 
the other hand, since ancient times, natural products are of medicinal importance and now 
they are in the limelight as new drug sources because of their diversity and availability. 
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Moreover, more than half of all approved chemical drug entities between 1981 and 2010 
are derived or inspired by natural product (Atanasov et al., 2015). 
  
Considering natural products as potential sources for drug development, in the 
present study, we evaluated antiviral activity of traditional medicinal plants from Asia 
and Africa against human influenza virus type A and B. Our study revealed that green 
Aspalathus linearis plant exhibit high activity against influenza virus.  
 
1.1 Influenza virus  
 The orthomyxoviridae family consists of influenza virus type A, B, C (IAV, IBV, 
ICV), thogo virus and isa virus (Szewczyk et al., 2014; Samji, 2009). IAV, IBV and ICV 
have been known to infect human, but only IAV and IBV are responsible for the annual 
epidemic. ICV cause very mild respiratory syndrome during childhood. IAV has wide 
range of host including swine, avian, and human, compare to IBV (human and seal) and 
ICV (human and swine). The wide range host of IAV led to pandemic due to their higher 
chance to acquire new genetic variant. This new genetic variant caused the occasional 
pandemic and resulted in severely damaged such as Spanish flu in 1918 which spread all 
over the world and caused more than 40 million deaths. IAV is divided into different 
subtype related to their HA and NA, which at present there are 18 serotypes of HA and 
11 serotypes NA (Tong et al., 2013). Meanwhile, IBV is divided into only two genetically 





Table 1. Protein encoded by various segments of influenza virus. 
 
The influenza virus is pleomorphic, usually occur in spherical or filamentous 
structure with size range from 80 – 120 nm.  The influenza genomes are negative 
polarity single-stranded RNA (ssRNA) which exist as complex, called viral 
ribonucleoprotein complex (vRNP). Each vRNP consists of one single-stranded RNA 
which associated with multiple nucleoprotein (NP) and single trimeric RNA dependent 
RNA polymerase (RdRp) composed of polymerase acidic protein (PA), polymerase basic 
protein 1 (PB1) and polymerase basic protein 2 (PB2). On the basis of genomes segments, 
IAV and IBV consist of eight segments meanwhile ICV consists of seven segments. 




Protein encoded by various gene segment of influenza virus 
Type A Type B Type C 
1 PB2 PB2 PB2 
2 PB1, PB1-F2 PB1 PB1 
3 PA PA P3 
4 HA HA HEF 
5 NP NP NP 
6 NA NA, NB CM1, CM2 
7 M1, M2 M1, BM2 NS1, NS2/NEP 
8 NS1, NS2/NEP NS1, NS2/NEP  
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Figure 1. Structure of influenza virus type A. Influenza A virus is an enveloped negative ssRNA 
virus. It contains eight segments of genome, each exists as complex form called vRNP which 
consists of RNA, NP and polymerase complex. Three different proteins are spiking on the surface 
of envelope which are HA, NA and M2 protein. M1 protein located at underneath of envelope 
which has function to hold the vRNP. 
 
  Influenza genomes are protected by envelope which is a lipid bilayer originated 
from human plasma membrane. The IAV has four different proteins on its envelope which 
are hemagglutinin (HA), neuraminidase (NA) and matrix 2 (M2) protein embed on its 
surface as spike like structure, and matrix 1 (M1) protein located underneath of envelope 
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which hold the vRNP as core protein (Figure 1). Whereas, IBV has five envelope proteins 
HA, NA, NB, BM2 and M1 protein. The BM2 and NB protein has similar function as M2 
protein of IAV. However, only BM2 protein is essential for IBV replication.  
 
1.2 Influenza virus replication 
  Influenza virus life cycle consists of following processes: 1. Adsorption, entry 
and uncoating; 2. Transcription of messenger RNA synthesis and viral replication; 3. 
Translation and post-translational processing of viral protein; 4. Virus assembly and 
release from the cells (Szewczyk et al., 2014; Samji, 2009). The scheme of influenza virus 
replication is shown in Figure 2. 
 
The first step of IFV life cycle started by attachment of HA protein to sialic acid 
of host cell. The HA protein is homotrimer which each monomer (HA0) consists of HA1 
and HA2 subunit which is linked by disulfide bond. To become infectious, HA0 need to 
be cleaved by proteolytic enzyme into HA1 and HA2 subunit (described in influenza 
pathology). HA1 is the receptor binding protein which will recognize and bind to the 
sialic acid in the surface of the host. The sialic acid is linked to galactose in specific 
linkage which known as SAɑ2,6Gal linkage in human, SAɑ2,3Gal linkage in avian, and 
both in swine. This linkage is important in specificity of HA recognition (described in 
influenza pathology section). The binding of HA1-sialic acid will trigger the receptor-
mediated endocytosis and entry of virus to the host cell through endosome. The low pH 
inside the endosome will promote the conformational change of HA0, trigger the 
exposure of HA2 subunit fusion protein into the membrane endosome and lead to fusion 
13 
 
of viral membrane and endosome (conformational changes of HA structure depicted at 
Figure 3). At the same time, the low pH condition will open the M2 proton-ion channel, 
acidifying the virus core, broke the binding between vRNP and M1 protein. 
 
Figure 2. Influenza virus life cycle. The cycle started by binding of HA particles of influenza 
virus to sialic acid receptor which expressed in the surface of the cell. The binding trigger the 
endocytosis and envelope fusion process, followed by influenza genomes release. These 
processes are involving HA, M2, M1 protein, and pH of endosome. The vRNPs are transferred 
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into nucleus through nuclear pore complex by NLS signal expressed by NP, PA, PB1 and PB2 
protein. The transcription and replication process occur inside the nucleus, followed by mRNA 
translation at cytoplasm and import of vRNPs into cell membrane. The last stage of replication 
cycle is assembly and release of new influenza virions to infect other cells. 
 
 Due to the requirement of cellular RNA for initiating the influenza mRNA 
synthesis, the replication and transcription of influenza genomes occur inside the nucleus. 
Therefore, the vRNPs should enter the nucleus. In addition, the replication of the genome 
inside the nucleus and encapsidation of influenza genome into vRNPs are also important 
for hiding from the RNA receptor retinoic acid inducible gene (RIG-1) which responsible 
in triggering antiviral response (Kell and Jr. Gale, 2015). The vRNPs are transported into 
nucleus through active-signal mediated transport. NP, PA, PB1, and PB2 protein contain 
the nuclear localization signal (NLS) which is important for vRNP nucleus transport. 
Although, it is still unclear which protein bind to cellular factor called importin alpha, 
beta, Ran and p10, but those protein will translocate vRNPs into the nucleus through 
nuclear pore complex (Whittaker, 2003). 
 
Once the vRNPs enter the nucleus, the genome transcription and replication are 
occurred. The transcription of vRNA into mRNA requires the priming which derived 
from cap-snatching of cell host mRNA. Thus, the virus will hijack the cap of host mRNA. 
The cap-snatching process is facilitated by viral cap-dependent endonuclease, reside in 
PA, PB1 and PB2 subunit. These endonucleases cut 10 to 13 nucleotides of 5’ ends cap 
mRNAs. The PB2 then bind the cap primer, followed by elongating the chain by PB1 and 
terminates at stretch of uridines upstream of 5’ non-coding region (NCR). Since the 
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association of 5’NCR with 3’NCR imposes the steric hindrance on the polymerases, 
causing it to transcribe uracil- rich region to poly A (Shapiro and Krug, 1988; Scull and 
Rice, 2010). The mRNA then exported to the cytoplasm for further translation to produce 
viral protein. The newly early synthesized viral protein such as NP, PA, PB1, and PB2 
then imported back to nucleus via their NLS and make complex with newly synthesized 
vRNA to form progeny vRNP.  
Figure 3. Conformational changes of HA structure. The native structure of HA (HA0) will be 
cleaved by proteolytic enzyme at position 324 to 329 of HA1 subunit (marked as scissor area). 
After binding of HA1 to sialic acid and exposure to low pH condition, the conformational 
structure will occur where the position of 56 to 77 and 106 to 112 of HA2 protein will change it 
conformation and expose fusion peptide (green blocks) to be inserted into cell endosomal 
membrane. HA1 subunit is indicated as salmon, purple and red color, HA2 subunit is indicated 






As the mRNA production and early protein synthesis accumulate, the switches 
from mRNA synthesis to complementary RNA (cRNA) which work as template for 
vRNA is occured. Several studies suggested that NP contributed in altering the panhandle 
secondary structure of RNA and associate directly with polymerase. Thus, possibly 
blocking the cap snatching activity and promoting the unprimed transcription, 
synthesizing the complete cRNA (Fodor et al., 1994; Newcomb et al., 2009). The report 
by Perez et al., 2010 identified the regulatory small RNA, called short RNA (svRNAs), 
which has function as essential prerequisite for vRNA synthesis. The svRNAs, likely 
synthesized from cRNA, will interact directly with polymerase complex (RdRp and NEP) 
to promote the replication of cRNA to vRNA (Scull and Rice, 2010; Peres et al., 2010). 
The newly synthesized vRNPs are also used as template for late protein transcription such 
as HA, NA, M1, M2, and NS2. 
 
In order to regulate virus assembly, late protein M1 are transported to the 
budding site. In addition, some of M1 proteins are also imported into nucleus through it 
NLS and bind with NP or vRNP through SUMOylation (protein post translational 
modification) of its C domain (Wu, 2011). To note, studies reported that export of vRNPs 
are correlated with the accumulation of HA protein which trigger the MPAK cascade 
apoptosis signal and the NS2 accumulation level which the C terminal of NS2 (Trp 78) 
link to N terminal of M1 which coded NLS (Watanabe et al., 2001; Watanabe et al., 2008; 
Shimizu et al., 2011; Hutchinson and Fodor, 2013). The vRNPs then exported to the 
cytoplasm via CRM1-dependent pathway which involving the binding of RNA-M1-NS2-
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CRM1 or vRNA-M1-Hsc70-CRM1 complexes and attached to recycling endosomes 
(RE) at the nuclear periphery. In RE the vRNPs will associate for segments formation, 
form complexes and transported into cell surface by microtubule organizing center 
(MTOC). There are two models that have been proposed for the segments formation 
which are “random packaging”, because of the presence of common structural elements, 
and “specific packaging”, specific structural features enabling them to be selectively 















Figure 4. Influenza virus assembly and release. The clustering of M1 protein in the inner side of 
membrane and accumulation of HA, NA and M2 protein in the outer side, initiate the membrane 
bending and fusion of apposed membrane, leading to fission and separation of bud from the cell. 
In addition, the budding process also involve host protein such as microfilaments, G proteins, and 




The last step for IFV replication is virus assembly and release. On the cytoplasmic 
face of membrane, M1 protein bind to cytoplasmic tail of HA, NA, M2 and to the 
membrane itself.  The accumulation of HA, NA and M2 protein in the outer side and 
M1 in the inner side of membrane is critical for the budding process. The clustering of 
M1 causes the membrane bending, initiate the budding as the apposing viral and cellular 
membrane is fused leading to fission and separation of the bud from the cell (Figure 4). 
In addition to viral factor, the host protein including ubiquitin, Tsg101, Vps4, Nedd4 and 
other members of vacuolar protein sorting pathway have been shown to be involved in 
the budding process (Nayak et al., 2004). After the particle release, NA protein will 
disrupt the linkage of HA and sialic acid of the host membrane. Thus, freeing the new 
virus particle to infect other cells. To note, NA protein will also remove the sialic acid 
from the surface of both virus particles and virus-infected cells. Thus, prevents self-
aggregation and reattachment to the virus-infected cell (Liu et al., 1995).  NA destroys 
HA receptors by cleaving the α-ketosidic bond, linking a terminal neuraminic acid residue 
to the adjacent oligosaccharide moiety (Gubareva et al., 2000). 
 
1.3 Influenza virus host 
 Influenza virus are host specific and facing a variety of barrier including innate 
immune responses, sialic acid receptor specificity as well as intracellular factors. 
However, the higher rate of mutation is worked as way for influenza virus to escape from 
those barrier, resulting in influenza re-infection. As mention above, IAV has wide range 
of host compare to IBV and ICV including wild birds, human, swine, horses, dogs, felix, 
mink, ferrets and marine mammals. The ability of IAV to also infect swine which contain 
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sialic acid receptors for both of human and avian, lead to its ability to reassort the IAV 
genomes of swine, avian, human and produce novel influenza virus with new antigenic 
properties which able to cause pandemic. In this section, the importance of those three 
hosts in maintaining stable IAV lineages are discussed.   
  
1.3.1  Birds 
Wild birds are natural host for all known IAV, as shown in Figure 5, and 
probably as the source of new variant pandemic (Webster et al., 1992, Wahlgren, 2011).  
Wild birds belong to Anseriformes (ducks, geese, swans, etc.) and Charadriiformes  
(gull and terns) families are considered as shelter of IAV gene pool. Meanwhile, 
domesticated birds such as chicken, turkeys become infected by IAV by adaptation or 
mutation of wild bird influenza viruses. 
 
In order to maintain the IAV genetical and antigenic diversity, the IAV infection 
on wildbirds usually occurred in asymptomatic-infection state (low pathogenic influenza 
infection).  In addition, this maintained-diversity have been associated with stable host 
switch to novel host such as horses, human, swine and lead to emergence of transmissible 
new virus lineages. The host switch event occurred from the mutation which the emergent 
virus must evolve as distinct eight- segment genomes constellation within new host and 




Figure 5.  Reservoir host for influenza virus. Wild aquatic birds are primordial natural reservoir 
for all influenza A virus. The transmission of influenza A virus from wild aquatic birds, birds, 
chicken, pigs to human are shown as dark grey arrow. The transmission to other species are shown 
as light grey arrow. (adapted and modified from Webster et al., 1992; Wahlgren, 2011). 
 
Although, mechanism by which avian influenza viruses cross the species barrier 
and infect human and mammals are still not fully understood, the sporadically changed 
of H5 and H7 low pathogenic into highly pathogenic avian influenza H5N1 on 1997 and 
H7N9 on 2013 which resulted in millions of poultry death and infected human, shown as 
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an evidence of avian genomes adaptation which affected by insertional mutation and 
frequently human exposure (Wright et al., 2007).    
 
1.3.2  Swine 
 The presence of SAα2,3Gal and SAɑ2,6Gal in epithelial cell lining of swine 
trachea, resulting on its susceptibility by avian and human IAV infection and 
simultaneously work as “mixing vessel” to generate new IAV variant which contain 
avian-swine-human influenza genome. Current pandemic on 2009, caused by novel 
H1N1 derived from two unrelated swine H1N1 viruses, was a result of reassorment 
between Eurasian swine flu lineage with North American swine lineage which acquired 
triple reassortant genomes from avian, swine, and human (Smith et al., 2009) as depicted 
at Figure 6.   
 
1.3.3  Human 
So far, seasonal influenza viruses which cause epidemic in human are confined 
into H1N1, H3N2 and H2N2 subtypes for IAV and Victoria and Yamagata lineages for 
IBV. However, influenza viruses especially IAV is evolved and adapted to the changes. 
Thus, it is successfully created not only the epidemic but also severe pandemic such 1918 
H1N1 pandemic known as Spanish flu, 1957 H2N2 pandemic known as Asian flu, 1968 
H3N2 pandemic known as Hongkong flu, 2009 H1N1 pandemic known as swine flu 
(Figure 4), and the occurance of re-emerging pandemic including 1997 H5N1 and 2013 
H5N7 avian virus, which still confined to animal-human transmission.  
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Figure 6. Genetic relationship between 2009 human H1N1 pandemic virus with swine, human 
and avian influenza virus. The gray arrows indicate the avian influenza virus genome derivation 
into human influenza virus or swine influenza virus. The solid red arrows indicate the 
evolutionary paths of human influenza virus. The dashed red arrows indicate the re- emerge of 
influenza virus. The solid black arrows indicate the evolutionary pathway of swine influenza virus. 
The solid black to red arrow indicate the swine origin of 2009 human H1N1 pandemic virus 
(modified from Morens et al., 2009). 
 
1.4 Influenza pathology 
In nature, the influenza virus infection is initiated by very low infection in human 
and animal host cell. The multiple cycles of influenza replication release new virus 
progeny which is critical for virus spread and disease manifestation. The infection of IAV 
and IBV cause acute respiratory infection with clinical feature such as fever, myalgia, 
headache, malaise, cough, sorethroat and nasal congestion. In the seasonal infection 
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(epidemic) the symptom will recover after several days up to 8 days. However, in the 
immune compromised patient and children, influenza virus shed can persist for longer 
duration than adult. Nevertheless, in industrialized countries the seasonal infection can 
affects 40% of total population and cause about 500 thousand deaths each year (Wright 
et al., 2007). IAV are considered as life-threatening infectious disease not only because 
annual infection but also because of its ability to reassort, which cause severe clinical 
manifestation and pandemic.  To note, pathogenicity of influenza virus is not only 
depended on the function of viral proteins but also on host immune response and 
commensal microflora which has been reported important for activation of pulmonary 
dendritic cells to induce immune response against IFV infection (Ichinohe et al., 
2011). The influence of viral proteins and host immune response into influenza 
pathogenicity are discussed below. 
 
1.4.1  Viral proteins 
The lack of RNA polymerase- proofreading activity makes the influenza gene 
easily to mutate. The accumulation of the mutant gene over the times, prompted the 
appearance of influenza virus with different antigenic properties, called as “antigenic drift 
process”, which responsible for seasonal IAV and IBV re-infection to people. Every year, 
influenza vaccines are designed based on antigenic drift prediction of seasonal influenza 
A and B. In addition to antigenic drift, the emergence of new IAV variant because of 
reassortment or “antigenic shift” which resulting in new IAV subtype with HA or HA 
and NA combination, has become a global treat as the pandemic occurred in the past 100 
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years: 1918 H1N1 Spanish influenza, 1957 H2N2 Asian influenza, 1968 H3N2 
Hongkong influenza, 2009 H1N1 swine influenza (Liu C et al., 1995).   
  
The sialic acid-galactose linkage is important factor for IAV reassortment. 
Human IAV are recognizing SAɑ2,6Gal linkage while the avian and equine IAV are 
recognizing SAɑ2,3Gal linkage. However, swine trachea has been reported to contains 
SAɑ2,6Gal and SAɑ2,3Gal, thus making it as effective machine for gene reassortment of 
human, avian, and swine IAV (Liu et al., 1995; Smith et al., 2009; Taubenberger and 
Kash, 2010). In addition, antigenic shift usually occurs in poultry which animals expose 
repeatedly to human, introducing the avian or swine IFV gene to human. By the time, 
human and animal exposure emerged the variant which previously not pathogenic 
become pathogenic to human such as H5N1 1997 avian flu and H1N1 2009 swine flu. 
Currently, H5N1 1997 avian flu still contained its infection from animal to human, but it 
is suggested that the novel antigenic variant can be transmitted efficiently through person 
to person if the adaptation to human by reassortment or whole genome adaptation is 
fulfilled (Taubenberger and Kash, 2010). 
  
The classification of IAV low and highly pathogenic is also depend on HA 
protein ability to infect respiratory system. In the seasonal case or low pathogenic 
influenza virus, HA bind to its receptor, i.e HA of seasonal IAV bind to SAα2,6Gal, which 
are expressed on the surface of upper respiratory epithelial cell resulting limited 
inflammation on upper respiratory tract which lead to mild diseases. However, in highly 
pathogenic influenza virus H5N1 1997 avian flu, mutation of its HA genome resulted into 
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virus ability to bind SAα2,3Gal of type 2 pneumocytes of human lung in the lower 
respiratory tract which increase the severity of pneumonia. Currently, the spread of H5N1 
from human to human is still restricted because the infection is localized in the lower 
respiratory tract. However, the possibility of further HA mutation which will increase its 
ability to infect SAα2,3Gal as well as SAα2,6Gal still become main concern. In case of 
highly pathogenic H1N1 2009, the HA substitution at D222G resulting in HA ability to 
infect ciliated bronchial cells which also result in severe pneumonia.  
  
 The cleavage site of HA which determining host protease susceptibility also 
influence its pathogenicity. The seasonal IAV possesses single arginine at the cleavage 
site to change the conformation of HA0 into HA1 and HA2 subunit. The single arginine 
can be cleaved by trypsin-like proteases which produced by respiratory and 
gastrointestinal cells. Meanwhile the highly pathogenic HA protein possesses multiple 
basic amino acid at cleavage site and susceptible to ubiquitous furin and PC6, which 
reside in the transgolgi network. Thus, highly pathogenic virus is able to cause systemic 














Pathogenic effect Reference 
HA H7N7 A143T Increased attachement to 
bronchial epithelial cells and 
alveolar macrophages in 
humans 





From α2,6 to α2,3 (loss of 
transmission ability) 
Tumpey et. al., 2007 
HA H1N1 
2009 
D222G From α2,6 to α2,3 infection of 
ciliated bronchial epithelial 
cells 
Liu et. al., 2010 
NA H3N2 R292K, 
E119V, 
N294S 
Loss of transmission ability, 
Oseltamivir-resistant 
Kiso et. al., 2004 





N66S Delay innate immune 
responses 
Conenello et. al., 
2007 
PB2 H5N1 T271A Increased polymerase activity 
in mammalian cell 
Bussey et. al., 2010 
PB2 H5N1, 
H7N7 
E627K Increased replication in 
mammalian respiratory tract 
Hatta et. al., 2007 
PB2 H5N1 D701N Increased ability to replicate 
in mice 
Li et. al., 2005 
PA H5N2 T97I Adaptation in mice Song et. al., 2009 
NS1 H5N1 P42S Increased in IFN antagonism Jiao et. al., 2008 
NS1 H3N8  R127K, 
V205I, 
N209D 
Increased replication and 
lethality in mice 
Pu et. al., 2010 
NS1 H5N1 D92E Low sensitivity to IFN and 
TNFα 




The RNA polymerase, NS1, and NA protein also participate in pathogenicity of 
IFV infection. Mutation of H5N1 RNA polymerase genomes A/Vietnam/1203/04, was 
demonstrated to be responsible for its pathogenicity (Fukuyama and Kawaoka, 
2011).  During influenza virus infection, the ssRNA virus in the cytoplasma will be 
recognized by retinoic acid-inducibe gene-I (RIG-1) and toll-like receptor (TLR 7) which 
will induce type-1 IFNα and active host viral response. However, the presence of NS-1 
virus protein interfere the signaling pathway by RIG-I by inhibiting the tripartite motif 
(TRIM) 25 in the ubiquitination of RIG-I. Study reported that NS-1 protein of H1N1 1918 
contributed to H1N1 1918 pathogenesis by effectively suppressed the RIG-I signaling 
and caused the blocking of type-1 IFNα production as innate immune response (Gack et. 
al., 2009). In addition, mutation of NS-1 amino acids at position of 123-127 will affect 
virus pathogenesis because this site is bind to protein kinase R (PKR) which work to 
down regulating the virus mRNA translation by phosphorylation of eukaryotic translation 
initiation factor 2 alpha (eIF2α).  The NA protein is important for virus release and 
spread into others cell. Thus, mutation and substitution of this protein will determine the 
disease severity. The effect of influenza virus protein mutation to ist pathogenesis is 
shown in Table 2. 
 
1.4.2  Host factor 
As mention above, host immune system protects the host from virus infection. 
In case of influenza infection, recognition of ssRNA by RIG-I signaling pathway is 
interfered by NS-1 protein result in reduction of IFNα response. Howevere, RIG-1 and 
TLR 7 are still able to up regulate several inflammatory cytokines and chemokines such 
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as IL-1β, IL-6, IL-8, TNFα, CCL2 (MCP-1), CCL3 (MIP-1α), CCL5 (RANTES), and 
CXCL10 (IP-10) (Fukuyama and Kawaoka, 2011; Perrone et al., 2008). 
 
The secretion of CCL2 chemokine will recruit the macrophages to the virus-
infected cell. The macrophages will bind to infected cell through its CCR2 (receptor of 
CCL2) and induce cell apoptosis via tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) - death receptor 5 (DR 5) interaction. The apoptosis induced by 
macrophage play a pathogenic role in pulmonary inflammation. It has been observed that 
in highly pathogenic avian influenza virus infection, neutrofils also present on the 
infected lung which suggested, the role of neutrofils in influenza pathogenecity (Tate e 
al., 2011). 
 
To maintain the homeostatis during influenza infection, cell surface receptor, 
CD200, is expressed on respiratory epithelial cells. The myeloids cells including 
macrophages, dendritic cells and granulocytes are expressing CD200 receptor called 
CD200R. The up regulation of CD200 on the cell surface will also up regulate the 
expression of CD200R at myeloids cells. The binding of CD200 and CD200R will down 
regulate the recruitments of immune cells and production of proinflammatory cytokines 
such TNFα and IL-6 which has role in expression of CD200R. Thus, result in reduction 
of lung inflammation. The inflammation of lung cell by cytokines and chemokines will 
also trigger the CD8T cell to produce IL-10 which is regulatory cytokine that inhibits 
inflammation responses and control the excessive lung inflammation. Simultaneously, 
myeloids and CD4T produce IL-27, IL-2 cytokines which both of it will synergistically 
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work with IL-10 to control the lung inflammation. The immune response will interact 
simultaneously to remove virus and maintain the homeostatis of respiratory immune 
response.  
 
However, the innate immune response has two distinct roles in pathogenesis of 
influenza virus infection. Uncontrolled innate immune response can lead to severe lung 
inflammation such as infection at immune deficiency patient. In contrast, adaptive 
immunity, which involves viral antigen-specific antibodies (B cells) and cytotoxic T 
lymphocytes activity efficiently eliminates virus infected cells and enables hosts to 
recover from viral infectious diseases. To note, H1N1 2009 infection caused severe 
diseases in middle-aged adults who had normal immune response. It had been proposed 
that severity of H1N1 2009 infection also caused by abnormal adaptive immune response 
as high amount of C4d deposition on bronchi was found (Fukuyama and Kawaoka, 2011; 
Monsalvo et al., 2011). 
 
1.5 Management of influenza infection  
Prevention by vaccination is a primary strategy to manage influenza infection. 
However, effectivity of influenza vaccine may reduce when the antigenic in vaccine is 
miss-matched with the circulating virus. Thus, anti-influenza therapy also hold important 
role in influenza virus management. This section will focus on superiority and problems 





1.5.1 Influenza vaccine 
 Influenza vaccination is the cornerstone for prevention and controlling the 
seasonal influenza infection especially in high risk peoples including children, elderly 
and immune compromised patient. At present, three classes of influenza vaccine are 
available: inactivated virus, live attenuated virus, recombinant hemagglutinin virus. 
These vaccines contain antigen from IAV H1N1 and H2N3 and dominant circulating 
lineage of IBV (trivalent vaccines) or both lineages of IBV (quadrivalent vaccines).  
 
Inactivated influenza vaccine (IIV) is subunit vaccine that contains purified HA 
protein administered intramuscularly or purified HA protein administered intradermally 
(Houser and Subbarao, 2015) and licensed for peoples ≥6 months of age and older. Based 
on antigenic content, IIV are further divided into trivalent (TIV) and quadrivalent 
influenza vaccine (QIV). TIV contains H1N1 and H3N2 subtypes of IAV and one 
predicted IBV, meanwhile QIV not only contains H1N1 and H3N2 of IAV but also 
contains two lineages of IBV which offer more protection against IBV. The introduction 
of IIV will induce the production of strain specific serum IgG. Live attenuated influenza 
vaccine (LAIV) is QIV administered intra nasally which contains live viruses with 
temperature sensitive and attenuating mutation. The attenuated virus of LAIV are 
restricted to replicate at temperature of lower respiratory tract but able to replicate at nasal 
cavity. The administration of LAIV will result in production of strain specific serum IgG, 
mucosal IgA and T cell responses. In addition, study reported that LAIV effective against 
not well matched of recommended vaccine antigen (Belshe et. al., 2000). Studies reported 
that LAIV is also effective to prevent influenza infection on children aged between 6 to 
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59 months. However, it is licensed only for peoples between 2 to 49 ages (Grohskopf et. 
al., 2014). FluBlok is recombinant HA vaccine which has been licensed for adult aged 18 
to 49 years old. The purified HA protein of this vaccine are expressed in insect cells from 
baculovirus vectors. Inspite of its specific aged regulation, recombinant HA vaccine has 
shorter manufacturing time compare to IIV and LAIV which would be valuable during 
pandemic response.      
  
The protection ability of vaccines is determined by its efficacy and effectiveness. 
Studies have shown that seasonal vaccine protection is most effective when vaccine strain 
matches with circulating strain, with effective rate about 50% until 60% in healthy adult 
and children and give greater benefit for children, older adults, pregnant woman, and 
immune compromised patients (Houser and Subbarao, 2015; Jefferson et al., 2014; 
Osterholm et al., 2012). However, there are several challenges of these vaccines including 
the failure to give optimal protection against pandemic influenza virus and time-
consuming vaccine design, insufficient protection for immune compromised patient and 
the need for annual vaccination.  
 
Several approaches have been developed to overcome those problem. In order 
to reduce dependency to embryonic eggs of IIV and LAIV, several licensed influenza 
vaccine has been produced outside from the eggs such as Flublock (HA recombinant 
vaccine) which the HA expressed by insect cell; Flucelvax which is current licensed IIV 
which the virus strain is grown using cell-culture technology (mammalian cell); and also 
development of next generation vaccine which do not need embryonated eggs (still in 
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clinical trial phase II) such as DNA vaccines, Viral vectors and virus-like particles (VLPs) 
(Houser and Subbarao, 2015, Lambert and Anthony, 2010). The lengthy time of vaccine 
production and requirement of annual vaccination are due to the antigenic changes of 
influenza virus. Month prior to vaccine production, the prediction of circulated virus is 
made, followed by virus strain production, inactivation, purification and dispensing into 
vials. The predictions of circulated viruses are the most important step. Currently the HA 
selection are decided using computational assay called antigenic cartography which is 
computational analysis of HAI assay data that provides a mathematical foundation for 
qualitative analysis of antigenic data (University of Cambrigde, 2014). However, on 2009 
pandemic, vaccine production and distribution was failed to be available on time. Thus, 
currently to avoid similar situation in the future pandemic, the stockpile of vaccine seed 
viruses (selected from epidemiology data) against different subtypes are done.  
 
Regarding to annual vaccine requirement and insufficient protection of immune 
compromised, currently researchers are trying to develop the universal influenza vaccine. 
A universal influenza vaccine is a hope for broadly cross-protective vaccine which could 
replace annual seasonal influenza vaccination and provide protection following the 
emergence of a novel influenza virus. Major target for universal vaccines are based on 
highly conserved external domain of M2 protein, and conserved epitope of hemagglutinin 
stem (Lambert and Fauci, 2010; Paules and Subbarao, 2017). Although M2 antibodies 
induced by natural infection are rare and short lived, they have been shown to provide 
broad protection against range of influenza viruses (Lee et. al., 2014). Vaccines focusing 
on M2 protein typically incorporate the protein into a VLP or express the protein in a 
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recombinant vaccine by fusing the gene encoding M2 or tandem repeats of the 
ectodomain of M2 (M2e) to a carrier protein or molecule (Lee et al., 2014). In addition, 
to overcome the insufficient protection of immune compromised patient, two strategies 
are currently being performed which are increase the antigen dose to boost immune 
response or adjuvant addition. Oil-in-water adjuvants which is generally well tolerated, 
such as MF59 and AS03, shown improving of immune responses of IIV particularly in 
infants (≥ 6 months) and older people (Camilloni et al., 2015; Nolan et al., 2014). In 
summary, above approaches are under development to improve or overcome the 
drawbacks of the currently licensed vaccines. 
 
1.5.2 Anti-influenza inhibitors  
 At present, anti-influenza drug represents a crucial strategy to control and 
prevent the seasonal and pandemic influenza infection as well as to cover limitation of 
the influenza vaccine such as time-consuming vaccine design, insufficient protection for 
immune compromised patients, and unpredictable antigenic changes which reduce the 
vaccine effectiveness (Eyer and Hruska, 2013).  In general, anti- influenza virus drug 
based on their original source can be divided into two classifications; synthetic analogues 
and substances derived from natural plants. Regarding to source classification, anti-
influenza virus drug also classified according to their target on viral replication cycle 
including hemagglutinin inhibitor, M2 ion channel blocker, RNA polymerase inhibitor 
and neuraminidase inhibitor (some of the anti-influenza drug chemical structures are 
depicted at Figure 7). The combination of different anti-influenza drugs such as 
amantadine, ribavirin and oseltamivir show enhancement of theurapeutic effects in vitro 
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and in vivo which could lead to crucial strategy for preparedness of future pandemic. In 
addition, host cell factor targeting drug are also extensively studied such as inhibitors of 
vacuolar proton-ATPase which render the viral M2 ion channels inactivation (Guinea and 
Carrasco, 1994), inhibitors of cellular proteases which block the proteolytic activation of 
haemagglutinin (Zhirnov et al., 2011), and blockers of the cellular ubiquitin-proteasome 
system (Dudek et al., 2010). However, host factor targeting drugs need to confirm 
extensively for its toxicity. In this section, anti-influenza drug according to their target on 
influenza virus life cycle is discussed.  
Figure 7. Chemical structures of approved anti-influenza drugs. A) Amantadine; B) Rimatadine; 
C) Favipiravir (T-705); D) Ribavirin; E) Zanamivir; F) Oseltamivir 
 
1.5.2.1 Hemagglutinin inhibitor 
 HA protein is responsible for initial influenza virus entry into the host cell. HA 
protein recognized the sialic acid receptor and trigger fusion of virus and membrane 
envelope of host cell. The inhibition of binding between HA protein and sialic acid 
A B C
D E F
A B C 
D E F 
35 
 
receptor has been demonstrated effective to suppress influenza virus replication such as 
inhibition by macromolecules composed of multiple sialic acid residues conjugated to 
glycan, glycopeptide or polyacrilamyde backbones (Narla and Sun, 2012); small organic 
compounds such as quinines, stachyflin antibiotic (Larson et al., 2012), benzamide and 
podocarpic acid derivative (Staschke et al., 1998). However, those molecules shown 
apparent cellular toxicity and strain specificity in vitro which caused by in ability of those 
molecules to target the highly conserved sites of HA molecule (residue 91, 98, 153 at 
bottom, 134 to 138 at 130-loop, 183, 190, 194 at 190-helix and 224–228 at 220-loop of 
HA1 globular head) (Yang et. al., 2013).   
  
Recently, the sialidase protein DAS181 has been identified as novel broad- 
spectrum HA inhibitor which shown promising antiviral activity at clinical phase II trial 
(IFV positive but otherwise healthy adult subjects) and was well tolerated in crossover 
trial in adult subjects with well-controlled asthma (Malakhov et al., 2006; Moss et al., 
2012; Colombo et. al., 2016). DAS181 is a 46 kDa recombinant fusion protein composed 
of sialidase catalytic domain derived from Actinomyces viscosus which fused with 
epithelial anchoring domain of human amphiregulin. DAS181 works through cleaving 
both of SAα2,6Gal and SAα2,3Gal from the host surface, preventing influenza virus 
attachment (Yang et al., 2013). Thus, DS181 may be less likely to induce drug resistance 






1.5.2.2 M2 ion channel blocker 
M2 ion channel blocker works specifically only at IAV and to note, it exhibits 
adverse effect such as causes gastrointestinal symptom (nausea, vomiting, diarrhea and 
loss of appetite) and neurological side effect (dizziness, nervousness, insomnia) which 
may attributable to its anticholinergic effects (Barr et al., 2008; Rosenberg and Casarotto 
et al., 2010; Galvao et al., 2012).  
 
Adamantane, the first synthetic anti influenza drug, and its derivatives, 
amantadine and rimantadine, are well known as M2 ion channel blocker inhibitor. 
Effectiveness of these drugs has been dramatically limited by the rapid spread of drug 
resistant mutations. Since 2006, after almost four decades of effective use of amantadine, 
resistance by influenza viruses of the A/H3N2 subtype exceeds to 90% in the United 
States, and virus mutants are as fit as the wild-type (wt) virus. The situation was even 
worst with the new 2009 pandemic H1N1 influenza (Duque et. al., 2011).  
 
1.5.2.3 RNA polymerase inhibitor 
Influenza RNA polymerase is a great target for anti-influenza virus drug 
development. Studied reported that PB1, protein important for RNA chain elongation, 
contains four conserved motif (shown in Figure 8) which found in all RdRp viruses and 
important for formation of pandemic influenza variant (Chu et al., 2012; Biswas et. al., 
1993; Poch et. al., 1989). Thus, PB1 can be a good target for development of new anti-
influenza drug. Presently, the RNA polymerase inhibitors are classified based on their 
mechanism of action which are; nucleoside analog for blocking the RNA chain elongation 
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and inhibitor of endonuclease and cap-bindings domain of the polymerase holoenzyme. 
The example of nucleoside analogs is favipiravir (T-705) which has been approved in 
Japan (AVIGAN ®, Toyama Chem. Co. Ltd.) but still on clinical trial in US, and ribavirin. 
In addition, favipiravir not only shown activity against other negative ssRNA virus such 
as arena- and bunya virus but also against some positive ssRNA viruses including noro- 
and falviviruses. It was also demonstrated that Favipiravir effective against zaire ebola 
virus infection in vivo (Oestereich et. al., 2014). However, the use of nucleoside analogs 
is accompanied by haemolytic anemia. Others class of RNA polymerase inhibitors which 
also under scrutiny are cap analogues, short capped oligonucleotides, and small organic 
compounds such as 4-substitued 2,4-phenylbutanoic acid and flutimide isolated from the 
fungus Delitschia confertaspora (Eyer and Huska, 2013).  
 
 
Figure 8. Sequence comparison of four conserved regions of PB1 protein of Influenza A/WSN33 
(IAV), B/Lee/40 (IBV), C/JJ/50 (ICV) and human immunodeficiency virus (HIV). The invariant 
sequences are boxed. (modified and adapted from Biswas et. al, 1993 and Poch et. al., 1989).  
 
1.5.2.4 Neuraminidase inhibitor 
As mention in the influenza virus replication section, neuraminidase protein 
(NA) has function to release and prevent the self-aggregation of new virus. Thus, the NA 
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inhibitor will cause the self-aggregation of newly budding virus and inhibit their spread 
into healthy cell. The original structure of NA inhibitor was found at 1970 which known 
as 2-deoxy-2,3-didehydroN-acetyl neuraminic acid (DANA, Sialic acid analoques). 
However, the design of highly effective inhibitor become feasible about 20 years later 
when three-dimensional structure of neuraminidase structure was disclosed. Zanamivir 
(Relenza®, Glaxo Smith Kline) become the first potent inhibitor which mimic 
neuraminidase natural substrate. However, related to its bioavailability, zanamivir is 
administered through oral inhalation. Oseltamivir phosphate, a pro drug (tamiflu®, F. 
Hoffmann-La Roche), was developed through modifications of sialic analogues and 
addition of lipophilic side chain which affect its bioavailability and allow to be 
administered orally (Moscona, 2005). The presence of zanamivir- and oseltamivir-
resistant virus has been responded by development of laninamivir (Inavir®, Daiichi 
Sankyo Co. Ltd.) administered by oral inhalation, and peramivir administered by 
intravenously (Rapiacta®, Biocryst pharmaceutical) which both of it had been approved 
in japan.  
 
To note, NA inhibitors represent a significant advance over the M2 inhibitors 
amantadine and rimantadine in influenza therapy. Thus, NA inhibitors are being used as 
prophylactic and treatment because of its broad-spectrum activity against IAV and IBV, 
less side effects compare to M2 ion channel inhibitor. However, the effect of NA inhibitor 
is limited because of the emergence of Oseltamivir-resistant already spread (described in 




1.6 Urgent need for new anti-influenza drug  
 The single amino acid changes of M2 ion channel at S31N position lead to 
adamantanes resistance which significantly increased from 0.4% in 1994 to 12.3% in 
2003 (Bright et al., 2005). Further, in 2006 amantadine and rimantadine-resistant virus 
was also found in 91% of clinical isolate of A H3N2 virus in united states as well as A 
H1N1 pandemic 2009 and previously A H5N1 1997 virus. It is believed that spread of 
resistant virus was due to over-the-counter prescription of adamantane and its derivative. 
Based on these facts, CDC issued the restriction and guideline of amantadine and 
rimantadine use for treatment of influenza infection.  
 
In the winter of 2007-2008 of northern hemisphere, the oseltamivir-resistant of 
seasonal influenza A H1N1 virus was emerged which associated with mutation at H274Y 
site. However, this resistant virus was unfit with previously evidence that mutation at 
H274Y reduced the virus infectivity. In case of A/Brisbane/59/07 H1N1 oseltamivir-
resistant virus, the transmission from person to person was not diminished and further 
replaced the susceptible virus easily and become the seasonal influenza virus for a year. 
Studied reported that the mutation at H274Y may resulted from mutation from site outside 
of active enzyme site, which exposed the folded NA surface and restore a balance function 
of HA and NA protein (Ciancio et al., 2009; Bloom et al., 2010). To note, mutation at 
H274Y not only cause oseltamivir-resistant but may also cause peramivir-resistant (Hurt 





The influenza A H1N1 oseltamivir-resistant seasonal virus was further replaced 
by oseltamivir–resistant A H1N1 pandemic 2009. However, approximately ~ 1% of 
clinical isolate of A H1N1 pandemic 2009 has been found to be resistant against 
oseltamivir in the worldwide (Hurt et. al., 2012). However, although the percentage of 
oseltamivir-resistant of pandemic 2009 remained relatively stable (Hurt et al., 2012; NIID, 
2015), increased of oseltamivir-resistant in immune compromised patient and children 
was observed in US from 11% in 2009-2010 to 74% in 2010-2011 (Stroms et al., 2012; 
Samson et al., 2013)  Studied shown, that A H1N1 pandemic 2009 virus not only 
contained mutation at H274Y but also at I223V or I223R which mutation at I223R site 
has been demonstrated related to zanamivir-resistant virus  (McKimm-Breschkin, 2012; 
Van der Vries et al., 2010; Rousset et al., 2010).  
 
In addition, anti-influenza drug resistant may not only occur during drug treatment 
but may also occur in the absence of drug treatment because of replacing the susceptible-
circulated influenza virus. Thus, threat of high prevalence of Adamantane –resistant virus, 
occurance of oseltamivir-resistant virus with susceptibility to zanamivir-, peramivir-
resistant and reduction of vaccine activity against miss-matched antigen, poses major 
challenges in clinical management of seasonal and pandemic influenza virus, highlighted 
the switches or combination of therapy to alternative medicine as urgent need. 
 
1.7 Natural product 
In the past decades, essentially success of new drug discovery came from 
medicinal chemistry invention which led to the need of development of chemical libraries 
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through combinatorial chemistry mainly from synthetic compounds.  The synthetic 
compounds are comparably easy to produce and resupply, and demonstrate good 
compatibility with established high throughput screening system. However, at the same 
time the number of new drug reaching the market has been in declining trend because of 
poor absorption, distribution, metabolism excretion or high toxicity (Ganesan, 2008), 
raising renewed scientific interest into natural products. In general, as mentioned before, 
sources for new drug discovery can be classified into two basic groups, synthetic 
analogues or compounds and substances derived from natural plant extracts. With regard 
to the considerable genetic and antigenic variability of the influenza virus, research has 
been predominantly focused on broad-spectrum antiviral drugs which are effective 
against a large variety of influenza strains and type. 
 
Natural product is a chemical compound or substance produced by living 
organisms, including plants, animals and microorganism, found in nature that usually has 
a pharmacological or biological activity. Historically, natural product has been used since 
long time ago as traditional medicine, dietary supplement and functional food. In the 
recent years, large number of small molecules such as phenols, polyphenols, terpenes, 
flavonoid and sugar contained in natural products showed promising antiviral activity as 
reported previously (Wu et al., 2015; Parhira et al., 2014; Palamara et al., 2005). The 
diversity and novelty make them rich sources for discovering new antiviral compound. It 
has been documented that large amount of natural products are possessing anti-influenza 
activity (Table 3). To date, more than half of all approved chemical entities as drug from 
1981 until 2010 is derived or inspired from natural product (Atanasov et al., 2015). 
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Meanwhile, the appearance of current available anti-influenza drug resistant and 
reduction of vaccine activity against miss-matched antigen, make the research for 
searching of new anti-influenza drug from natural products need to be continued. 
 
Table 3. Natural products with anti-influenza activity. 
Plants Compounds Targets Reference 
Thalictrum simplex Pavine alkaloid (–)-
thalimonine 
Late protein synthesis Serkedjieva 
and Velcheva, 
2003. 
Curcuma longa Curcumin 
(diferuloylmethane) 
Direct effect on viral 
particle, hemagglutinin 
inhibition 
Chen et. al., 
2010 
Calotropisgigantea Lignan glycoside Inhibition of NF-
kBpathway and viral 
ribonucleoproteins 
nuclear export 
Parhira et. al., 
2014 
Rheum palmatum Aloe-emodin (anthraquinon) NS1 antagonis effect Li et. al., 
2014. 
Sophoraflavescens Aloperine (lupine 
alkaloid) 
Neuraminidase inhibitor Ryu et. al., 
2008 
 
1.8 Aim of study 
In the present study, in order to find natural products which possess anti-
influenza activity, green and red Aspalathus linearis leaves, Acacia nilotica pods and 
dried-hot water extract of Uncaria gambir were selected for anti-influenza evaluation. 
These plants were selected not only because of its abundant availability in Africa and Asia 
countries but also numerous studies reported its biological activity against many 




  A. linearis is a leguminous plant belonging to the fabacea family which is native 
to the western-cape of South Africa. Mixtures of dried leaves and flowers from this 
particular plant, known commonly as Rooibos tea, have been used as traditional 
medicines and a common health beverage in Europe, Africa, and Japan (Mackay and 
Blumberg, 2007). Traditionally, A. linearis is used to cure infant colic, improve appetite, 
reduce nervous tension and heartburn, and alleviate dermatological problems such as 
eczema. It current use as a common health beverage is particularly popular because of the 
absence of alkaloids, particularly caffeine, and a low concentration of tannin (Joubert, 
1996; Bramati et al., 2003). Two types of A. linearis is well known based on their color. 
The color of unfermented A. linearis is green while the fermented is red. The color change 
happened due to fermentation process where the oxidation of polyphenols constituents 
occurred. A. linearis has been reported to contain high amounts of phenols such as 
aspalathin, nothofagin, isoorientin, orientin, vixetin and rutin, along with a much lower 
content of quercetin and luteolin (Joubert, 1996; Bramati et al., 2003; Joubert and de Beer, 
2012; Krafczyk and Glomb, 2008). Numerous studies have demonstrated the biological 
activity of A. linearis. Of particular note is that this plant has been reported to exhibit anti-
mutagenic activity of aflatoxin B1 and 2-acetylaminofluorene in Salmonella typhimurium 
(Van Der Merwe, 2006), anti-cancer activity in rat liver by reducing the number of loci 
in liver cells (Marnewick et al., 2009), and anti-rotavirus activity (Knipping et al., 2012) 
which was attributed to its phenol content. It has also been reported that an aqueous 
extract of A. linearis exhibits antioxidant activity which interferes with stress-reducing 
activity in rats in which stress was induced by immobilization (Hong et al., 2014). Nakano 
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et al. further showed that the polysaccharide content of the alkaline extract of A. linearis 
could interfere with the binding of HIV-1 to MT-4 cells (Nakano et al., 1997).  In 
addition, previous studies have reported that quercetin was able to interfere with influenza 
virus infection (Wu et al., 2015). 
 
  A. nilotica, belongs to the family Fabaceae, is native Africa plant which widely 
distributed throughout the tropical and subtropical plains all over arab peninsula and 
Indian subcontinent (Farzana et al., 2014; Rajvaidhya et al., 2012). Almost all its parts 
such as root, bark, leaves, flower, gum, pods etc are used in folk medicine for bleeding 
diseases, prolapse, leucorrhoea, and antifungal. Reported experimental studies showed its 
activity as antihypertensive, antispasmodic, antibacterial, antifungal, antioxidant and 
antiviral. The phytochemical studies reveal that A. niloctica contains tannins, terpenoids, 
crude protein kaempferol, alkaloids, phenols, volatile oil, essential oil, steroids, oleosins, 
terpenes, resins saponins, steroids, triterpenoid and flavonoids. Its pod was reported 
contain tannins and polyphenolic compounds (Raheel et al., 2014; Bargali and Bargali, 
2009). Aqueous and ethanol extracts of A. nilotica stem bark was reported to possess 
antimicrobial activity, suppress HIV-1 replication and hepatitis C virus (Sharma et al., 
2014; Nutan et al., 2013; Rehman et al., 2011) and methanolics extracts of its seeds shown 
anti-HSV type 1 and 2 activity (Parmar et al., 2010).  
 
  U. gambir, belongs to rubiaceae family, is plant species which distributed in 
Indonesia, Singapore and Malaysia (Elfahmi et al., 2014; Andre et al., 2013). U. gambir 
contains aboundant amount of procyanidin, catechin and quercetin which has been 
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reported to exhibit antiviral activity (Sazwi et al., 2013). Traditionally, U. gambir is used 
to treat sorethroat, spongy gums, dysentry, athero-sclerosis, obesity and deafness (Vital 
and Rivera, 2009). To date, U. gambir has been reported to exhibit antimicrobial, 
antinematoda, antidiarrhea activity (Zhang et al., 2015), however its antiviral activity is 
still unknown.  
 
The confirmation of A. linearis, A. nilotica and U. gambir activity against 
influenza virus infection can convert their daily consumption as a beverage to be a 
prophylactic or therapeutic treatment. Further identification and purification of their 
effective component may lead to development of new antiviral agents. Considering the 
emergence of anti-influenza resistant and potential of these traditional medicine, in the 














CHAPTER 2: MATERIAL AND METHODOLOGY 
 
2.1 Reagents 
Oseltamivir    - F. Hoffmann-La Roche, Switzerland 
Crystal violet    - Nacalai tesque, Japan 
Water soluble Tetrazolium (WST-1) - Dojindo, Japan 
1-methoxi PMS    - Dojindo, Japan 
MEM     - Wako, Japan       
DMSO     - Wako, Japan 
Fetal bovine serum (FBS)   - Gibco, USA 
Penicillin G Potassium   - Nacalai tesue, Japan 
Streptomycin sulphate   - Nacalai tesque, Japan 
Sodium bicarbonate (1%NaHCO3)  - Nacalai tesque, Japan 
Trypsin     - Worthington, USA  
Disodium Ethylene diamine tetra Acetate - Wako, Japan 
Red Blood Cell    - Nippon Bio-test Lab., Japan 
Ethanol     - Nacalai tesque, Japan 
Ethyl acetate    - Wako, Japan 
n-Hexane    - Wako, Japan 
 
2.2 Material & Equipment 
Axiovert 25 Inverted Fluorescence microscope - Carl Zeiss, German 
Bacterial dish (90 mm)    - Full steril, Japan 
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Cell culture plates (6,12-wells)   - Nunclon, Denmark 
Cell culture plates (96-well)   - True line, USA 
Cell culture dish (90 mm)    - Nest, China 
Centrifuge Kubota KS-8000   - Kubota, Japan 
Centrifuge Beckman J-12    - Beckman, USA 
Rotary evaporator    - Rotavapor, Switzerland 
Class II A/B3 Biological safety Cabinet ASC-198 - Astec, UK 
High speed refrigerate micro centrifuge MRX-152 - Tomy, Japan 
Effendrof evaporator    - Effendrof, USA  
Infinite M200 Tecan plate reader   - Wako, Japan 
Milli-Q Water Purification System  - Millipore, France 
Multi pipette channel (p2-200)   - Calibra 852, Swiss 
Microscope phase-contrast   - Carl Zeiis, German 
Pipette man (P20, P200, P1000)   - Gilson, France 
 
2.3   Methodology 
2.3.1  Reagents, sample, cells and virus  
2.3.1.1 Reagents preparation 
Minimum essential medium preparation 
    Eagle’s minimum essential medium (MEM) was purchased from Wako (Japan), 
supplemented by 100 units/ml of penicillin G, 100 µg/ml of streptomycin sulfate and 





Oseltamivir sulfate was purchased from F. Hoffmann-La Roche Ltd. (Basel, 
Switzerland) and dissolved in ultrapure water to a concentration of 24 mM and stored at 
-30 °C.  
 
Crystal violet preparation 
 Crystal violet (CV) was purchased from Wako Pure Chemicals Industries, Ltd 
(Japan). 0.5% CV was prepared as following: 2.5 g of crystal violet granule was added 
into plastic bottle containing 500 mL of ultrapure water, shaked at room temperature for 
5 min and stored at light-protected area. 
 
WST-1 and 1- methoxy PMS preparation 
 Water soluble tetrazolium 1 (WST-1) and 1-Methoxyphenazine methosulfate (1- 
methoxy PMS) were purchased from Dojindo Molecular technologies, Inc. (Kumamoto, 
Japan). 5.4 mM of WST-1 was prepared as follows: 57.9 mg of WST-1 powder was added 
into 50 mL tube containing 16 mL of 20 mmol of HEPES buffer (pH 7.4) and shaked 
until WST-1 dissolved. 2 mM of 1-methoxy PMS was prepared as follows: 7 mg of 1- 
methoxy PMS was added into 15 mL tube containing 10 mL of ultrapure water and shaken 
until dissolved. The WST-1 and 1-methoxy PMS were stored at 4°C and protected from 






1% Sodium bicarbonate preparation 
 Sodium bicarbonate (NaHCO3) was purchased from Wako Pure Chemicals 
Industries, Ltd. 1% NaHCO3 solution was prepared directly before experiment as follows: 
1 g of sodium bicarbonate was added into 500 mL beaker glass, followed by addition of 
100 mL ultrapure water. The solution was mixed well until sodium bicarbonate 
completely dissolved.   
 
2.3.1.2 Sample preparation  
     Dried-organic green and red A. linearis leaves were manufactured at South 
Africa and purchased from All Tea RTU Co. Ltd (Nagano, Japan). Dried-hot water extract 
of U. gambir leaves and shoot were manufactured by Tochimoto Amamido Ltd and 
purchased from Oriental Chinese Medicine Co. Ltd (Oita, Japan).  A. nilotica pods were 
kindly provided by Professor Nobuyuki Kobayashi, Nagasaki University, Japan.  
 
Hot water and alkaline extraction 
One gram of A. linearis leaves, grinded A. nilotica pods and U. gambir dried hot 
water extract were each transferred into different 15 mL tube. 10 mL of boiled ultrapure 
water was added to each tube and shaken at 85°C for 3 hours using Taiyo personal shaker. 
The mixture was then centrifuged at 1000 ×g for 30 min (Kubota KS-8000, RS-3000 
rotor). The supernatant was collected, filtered using 0.45 µm filter, designated as hot 




The residue of A. linearis and A. nilotica was dried for 2 days, measured and 
further shaken in 15 mL of ultrapure water containing 1% sodium bicarbonate (NaHCO3) 
at 45°C for 4 hours. After re-centrifugation and filtration using a 0.45 µm filter, the 
supernatant designated as alkaline extract of A. linearis or A. nilotica and stored at -80°C.  
 
Meanwhile the alkaline extraction for U. gambir was performed as follows: one 
gram of U. gambir dried-hot water extract were grinded, measured and transferred into 
15 mL tube. 10 mL of ultrapure water containing 1% sodium bicarbonate (NaHCO3) was 
added into the tube and mixed using Mutator Murata at 45°C for 4 hours. The suspension 
was then centrifuged at 1000 ×g for 30 min. The supernatant then filtrated by 0.45 µm 
filter and designated as alkaline extract and stored at -80°C. 
 
Ethanol extraction 
 One gram of A. linearis, A. nilotica, and U. gambir were each suspended in 10 
mL of 70% ethanol (EtOH) and mixed using Mutator Murata at room temperature for 20 
hours. The mixture was then centrifuged for three times at 8740 × g for 15 min (Beckman 
J2-21 centrifuge, JA-20 rotor). The supernatant was separated into new 15 mL tube by 
filtration using 0.45 µm filter and aliquot into 1.5 mL (400 µL/tube). The aliquot then 
concentrated by effendrof concentrator for 1 hour 20 min. The pellet stored at -80°C and 






Ethyl acetate extraction and n-hexane extraction 
   One gram of A. linearis or A. nilotica or U. gambir dried extract were measured 
and transfer into glass bottle and suspended in 10 mL of ethyl acetate (EA) or n-hexane, 
and shaken at room temperature for 20 hours. The supernatant was separated into new 
glass bottle by decantation, centrifuged for three times at 8740 ×g for 15 min and aliquot 
into 1.5 mL effendrof (400µL/tube). The aliquot then concentrated by effendrof 
concentrator for 30 min. The pellet was stored at -80°C and diluted with 1% DMSO 
before use. 
 
2.3.1.3 Cells maintenance and virus preparation 
Madin-darby canine kidney (MDCK) cells were grown and maintained in MEM 
supplemented by 5% fetal bovine serum (FBS), at 37ºC in 5% CO2 atmosphere.  
 
The influenza A/Wisconsin/33 (A/WSN/33) and influenza A/Puerto Rico/8/34 
(A/PR/8/34) were propagated in MDCK. A/PR/8/34 was grown in the presence of 2.5 
µg/mL trypsin (Sigma-Aldrich Co., St. Louis, MO) and the culture supernatants were 
stored at -80°C. The clinical isolates of influenza virus from 2009 pandemic patient in 
Japan (A/Nagasaki/HA-6/2009, A/Nagasaki/HA-16/2009, A/Nagasaki/HA-33/2009, and 
A/Nagasaki/HA-58/2009 oseltamivir-resistant) were propagated in a ten-day-old 
embryonic egg for 48 hours, followed by collection of the allantoic fluid and stored at -
80°C. The laboratory-adapted strains of influenza B/Brisbane/60/2008, B/Lee/40 and 
clinical isolates of influenza B virus from Japan (B/Okinawa/4/2014 oseltamivir-resistant, 
B/Okinawa/6/2014, B/Okinawa/7/2014 oseltamivir-resistant, and B/Okinawa/8/2014) 
52 
 
were propagated in MDCK cells. The culture supernatants then stored at -80°C. Viral titer 
was determined by calculating the 50% tissue culture infectivity dose (TCID50). 
 
2.3.2 Virus titration (50% Tissue culture infectious dose-TCID50) 
MDCK cells (3×104 cells per well) were seeded in 96-well culture plate and in 
MEM containing 10 % FBS and incubated overnight. The cells were washed using 100 
µL of MEM followed by addition of 100 µL of 10-fold serial dilution of virus in serum-
free MEM supplemented with 1% vitamin. The plate was incubated at 37°C, 5%CO2 for 
3 days, then fixed with 70% EtOH at room temperature for 5 min and stained with 0.5% 
CV at room temperature for 5 min. The virus titer was determined by reed-muench 
statistical method (Reed and Muench, 1938). 
 
In the case of A/PR/8/34 and clinical isolate of influenza virus from 2009 
pandemic patient in Japan (A/Nagasaki/HA-6/2009, A/Nagasaki/HA-16/2009, 
A/Nagasaki/HA-33/2009, and A/Nagasaki/HA-58/2009 oseltamivir-resistant), TCID50 
was performed as explained above, but with addition of 5 µg/mL trypsin in serum-free 
MEM supplemented by 1% vitamin. 
 
2.3.3 Anti- influenza virus activity and cytotoxic assay   
2.3.3.1 Crystal violet assay 
Cellular toxicity was evaluated using a 96 well-culture plate. The 3× 104 MDCK 
cells per well in MEM supplemented by 10 % FBS were seeded and incubated at 37 °C, 
5% CO2 overnight. The supernatant was aspirated and washed by serum-free MEM, 
53 
 
followed by the addition of 100 µL of serum-free MEM containing 1% vitamin and 100 
µL of two-fold serial dilution of extracts. The mixtures were incubated at 37°C in 5% 
CO2 for 3 days. The supernatant was then aspirated and the cells fixed with 70% ethanol 
and then stained with 0.5% CV solution. Cells were then dried and absorbance was 
measured using Infinite M200 Tecan plate reader at 560 nm wavelength. The CC50 was 
then calculated by linear regression analysis using Microsoft Excel software.  
 
The anti-influenza assay was carried out using a 96 well-culture plate. The 3× 
104 MDCK cells per well in MEM supplemented by 10 % FBS were seeded and incubated 
at 37°C, 5% CO2 for overnight. The supernatant was then aspirated and washed with 
serum-free MEM, followed by addition of 100 µL serial dilutions of the extracts and 100 
µL of influenza virus in serum-free MEM supplemented by 1% vitamin (MOI of 0.002). 
The cells were then incubated at 37°C, 5% CO2 for 3 days. The supernatant was removed 
and the cells fixed with 70% ethanol and stained with 0.5% CV. Cells were dried and 
absorbance was measured as described above. The percentage of relative optical density 
(OD) value was calculated from the ratio of absorbance in the presence of virus to 
absorbance in the absence of virus. The IC50 was then calculated by linear regression 
analysis using Microsoft Excel software. The SI was calculated as ratio of CC50 to IC50 
values. 
 
2.3.3.2 WST-1 assay 
  WST-1 assay was performed to confirm and evaluate cellular toxicity and anti-
influenza activity of green A. linearis alkaline extract. Seeding of cells and addition of 
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extracts was performed as described in CV assay. After 3 days incubation, the attached 
cells were washed two times with 100 µL of serum-free MEM, followed by addition of 
100 µL of serum-free MEM supplemented by 1% vitamin and 10 µL of WST-1 and PMS 
mixture. The plate then shaken by automated plate shaker for 20 seconds and incubated 
at 37°C, 5% CO2 for 30 min. The color absorbance then measured using Infinite M200 
Tecan plate reader at 450 nm and 650 nm wavelength. The CC50 and IC50 was then 
calculated by linear regression analysis using Microsoft Excel software. 
 
2.3.3.3 Hemagglutination assay  
Fifty microliters of two-fold serial dilutions of virus culture supernatant was 
incubated with 50 µL of 5% red blood cell (RBCs) in 96-well micro titer plate and 
incubated at room temperature for 1 hour. Hemagglutination was determined by visual 
examination. Hemagglutinated RBCs diffusely spread in the microtiter well while non-
hemagglutinated RBCs settled at the bottom of the well. The hemagglutinin unit was 
calculated from the last dilution with visible hemagglutination. 
 
2.3.4 Mode of action 
2.3.4.1 Time-of-addition assay 
  MDCK cells were seeded at a concentration of 2 × 105 cells per well into 24 well-
culture plates and incubated overnight. The cell monolayer was then infected with 
A/WSN/33 at MOI of 0.001 and treated with a 5% alkaline extract of green A. linearis, 
or 20 µM of oseltamivir at different times during a single replication cycle as follows:  
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a) Control: Cells were infected with MOI of 0.001 in 100 µL of serum-free MEM at 37°C 
for 1 hour. Unattached viruses were removed and the cells were washed twice with serum-
free MEM, and 1 mL of serum-free MEM was added.  
b) Pretreatment of cells: 100 µL of 5% alkaline extract of green A. linearis or 20 µM of 
oseltamivir were added to the cells and incubated at 37°C for 1 hour. The supernatant was 
aspirated and the cells were washed two times with serum-free MEM. The cells were 
infected with MOI of 0.001 in 100 µL of serum-free MEM at 37°C for 1 hour. Unattached 
viruses were removed and the cells were washed twice, followed by addition of 1 mL of 
serum-free MEM. 
c) Pretreatment of virus: 100 µL of 5% alkaline extract of green A. linearis or 20 µM 
oseltamivir containing approximately virus equal to MOI of 0.001 were incubated at 4°C 
for 1 hour before addition to cells and further incubation at 37°C for 1 hour. Unattached 
viruses were removed and the cells were washed twice, followed by addition of 1 mL 
serum-free MEM.   
d) Treatment during infection: 100 µL of 5% alkaline extract of green A. linearis or 20 
µM of oseltamivir and virus equal to MOI of 0.001 were added to the cells simultaneously 
and incubated at 37°C for 1 hour. Unattached viruses were removed and the cells washed 
twice with MEM followed by the addition of 1 mL of MEM.  
e) Treatment after infection: Cells were infected using 100 µL of virus equal to MOI of 
0.001 at 37°C for 1 hour.  Unattached viruses were removed and cells washed twice with 
serum-free MEM. Following infection, 1 mL of serum-free MEM containing 5% alkaline 
extract of A. linearis, or 20 µM of oseltamivir, were added at different time periods, as 
shown in Figure 2.  
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Twelve hours after infection, the supernatant from different time points of alkaline extract 
or oseltamivir treatment were collected and subjected to viral titration using TCID50 assay. 
The viral titer was then calculated using the Reed-Muench method. The relative viral 
yield value was calculated as the percentage ratio of treatment relative to control. 
 
2.3.4.2 Virucidal assay 
   Virucidal assay was performed by incubating 100 µL of approximately 1×106 
TCID50/mL of A/WSN/33 with equal volume of green A. linearis alkaline extract at 
concentration of 2.5% and 10% and incubated at 37°C for 1 hour. The mixture was further 
diluted a hundred times in MEM+vit. The dilution was further subjected for virus titration 
by TCID50 assay as explained above.  
 
2.3.4.3 Hemagglutination inhibition assay 
Hemagglutination inhibition (HI) assay was performed as previously described. 
In briefly, 50 µL of two-fold dilution of green A. linearis alkaline extract was prepared 
and mixed with an equal volume of 100 HA units of A/WSN/33 in 96-well micro titer 
plate. After incubation at 4°C for 1 hour, 50 µL of RBCs were added, mixed and incubated 
at room temperature for 1 hour to allow hemagglutination to occur.   
 
2.3.5 Ultrafiltration 
  In order to characterize the molecular weight of active compound(s) present in 
green A. linearis alkaline extract, molecular weight ultrafiltration was performed as 
follows: 400 µL of extract were transferred into 1.5 mL tube of 100-kDa or 50-kDa or 
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10-kDa ultra filtration devices, followed by centrifugation at 9000 ×g at 4°C until 90% 
of extract pass the filter (approximately 45 min). The filtrate was collected and stored at 





















CHAPTER 3: RESULTS 
 
3.1   Extraction 
In the present study, we evaluated green and red Aspalathus linearis (A. linearis) 
leaves, Acacia nilotica (A. nilotica) pods and Uncaria gambir (U. gambir) dried-hot water 









Figure 9. Appearance of samples evaluated for their anti-influenza virus activity. A) Green A. 
linearis leaves; B) Red A. linearis leaves; C) A. nilotica pods; D) Dried-hot water extract of U. 
gambir leaves and shoot.   
 
Two different forms of samples which are plant and dried-hot water extract were 
prepared as described in materials and methods section. The appearance of raw materials 
is shown in Figure 9. Extraction of samples were carried out using hot water and alkaline 
solution, 70% ethanol, ethyl acetate, and hexane solvents. Extracts obtained using the 
different solvents showed different colors due to the differences in their phytochemical 
constituents and concentrations. In all plant samples, alkaline extract showed the deepest 
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dark coloration while hexane had the lightest color. The color appearance of all extracts 





















Figure 10. Extracts prepared using different solvents. Different color of extracts was due 
to differences of phytochemicals constituents and concentrations.   
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 3.2   Anti-influenza screening of plants extracts 
The cellular toxicity and anti-influenza activity of plants extracts were evaluated 
using crystal violet method which represents a quick and simple technique for the 
quantification of cell death. The cells that undergo cell death lose their adherence and are 
subsequently lost from the population. Thus, reducing the amount of crystal violet 
staining in a culture. The attachment of cells in the presence of extract with or without 
addition of influenza A/WSN/33 at MOI of 0.002 was evaluated after three days 
incubation at 37℃, 5% CO2.  
 
Figure 11 shows the crystal violet staining results and relative OD value of   
cells infected with influenza A/WSN/33 (MOI of 0.002) in presence or absence of various 
plant extracts. At some plates, decreased of CV stain color was followed by increased of 
CV stain color at higher concentration. This phenomenon was due to artifact color derived 

















Figure 11. Cellular toxicity and anti-influenza activity of tested extracts.Almost all tested extracts 
except ethyl acetate and n-hexane extract of A. linearis and n-hexane extract of A. nilotica and U. 
gambir,showed influenza virus inhibition. Confluent MDCK cells were treated with the extracts 
at different concentrations in the presence or absence of MOI of 0.002 of A/WSN/33 infection. 
The cells were further incubated at 37°C in 5% CO2 atmosphere for 3 days. The supernatant was 
aspirated, followed by 70% ethanol fixation process at room temperature for 5 minutes. The fixed-
cells were further stained by 0.5% CV staining at room temperature for 5 minutes. The colored-
cells were washed and dried, followed by measurement of OD value at 560 nm. The CC50 and 
IC50 values were calculated using linear regression system by Microsoft Excel software. The CV 
staining result and dose-response curve in the absence and presence of different plant extracts: A) 
green Aspalathus linearis; B) red Aspalathus linearis; C) Acacia nilotica; D) Uncaria gambir. 
 
Almost all tested extracts except ethyl acetate and n-hexane extracts of green- 
and red- A. linearis, and n-hexane extracts of A. nilotica and U. gambir inhibited influenza 
virus with varied cellular toxicity as shown in Table 4.  The extracts of A. linearis 
showed higher SI value compare to other plant extracts, in particular green A. linearis 
alkaline extract with SI value more than 12.5. Thus, this extract was selected for further 
experiments to evaluate its broad-spectrum activity and mode of action.       










Table 4. Cellular toxicity and anti-influenza activity of extracts. 
Sample Extraction Method 












Hot Water    7.70 0.75 10.3 
Alkaline >20 1.60 >12.5 
Ethanol    1.00 0.12 8.3 
Ethyl acetate  >10 NAc NA 
n-Hexane >10 NA NA 
Red Aspalathus 
linearis 
Hot Water    4.20 0.30 14.0 
Alkaline    3.24 0.24 13.5 
Ethanol     5.50 0.46 11.9 
Ethyl acetate     8.87 NA NA 
n-Hexane  >10 NA NA 
Acacia nilotica 
Hot Water    0.15 0.03 5.0 
Alkaline     0.14 0.03 4.6 
Ethanol     0.14 0.03 4.6 
Ethyl acetate     1.10 0.17 6.5 
n-Hexane  >10 NA NA 
Uncaria gambir 
Hot Water    0.20 0.05 4.0 
Alkaline    0.42 0.05 8.4 
Ethanol     0.23 0.03 7.7 
Ethyl acetate  >10 1.80 > 5 
n-Hexane  >10 NA NA 
aCC50 is 50% cytotoxic concentration of extract, IC50 is 50% inhibitory concentration of extract 
against MOI of 0.002 of A/WSN/33 infection. CC50 and IC50 are represented as % v/v. bSI is 




3.3   Cellular toxicity and anti-influenza activity of green A. linearis 
alkaline extract 
The extract color component(s) was observed interfering the CV staining result 
as shown in Figure 11. Thus, we also evaluated cellular toxicity and anti-influenza activity 
of green A. linearis alkaline extract using WST-1 assay. In CV assay, the dye bind to 
protein of fixed cells. Meanwhile, WST-1 assay which is theoretically similar to MTT 
assay but has better solubility, is based on enzymatic cleavage of tetrazolium salt to 
formazan by cellular mitochondrial dehydrogenases in the living cell. The comparison of 
cellular toxicity and anti-influenza activity of the extract which evaluated using CV 
staining and WST-1 assay is shown in Figure 12A, B. The results showed that CC50 value 
obtained from CV and WST-1 assay were 33.6±14% and 34.6±8%, respectively (Figure 
12A). Meanwhile IC50 value obtained from CV and WST-1 assay were 1.6±0.2% and 
1.4±0.0%、respectively (Figure 12B). These results indicate that CV and WST-1 assay 
result were comparable and CV assay can be used in determination of cell viability.    
 
The microscopic observation of the cells treated with green A. linearis alkaline 
extract in the absence or presence of virus after 3 days incubation at 37°C, 5% CO2 is 
shown in Figure 12C. In the absence of virus, addition of 20% of the extract resulted in 
bigger cell morphologies when compared to control (without extract and virus), indicating 
the slight reduction of cells viability. Most of the cells were detached in the presence of 
40% of the extract. In the presence of virus, addition of 1.8% of the extract resulted in 
reduction of cell detachment when compared to control infection (without addition of 
extract) and more pronounce in addition of 5% of the extract. The microscopic 
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observation was comparable with relative OD value result.  
 
To confirm the assay, oseltamivir was used as a positive control as shown in 
figure 12D. Anti-influenza activity of oseltamivir was evaluated using CV assay and IC50 







Figure 12. Evaluation of cellular toxicity and anti-influenza activity of green A. linearis alkaline 
extract using CV, WST-1 assay and microscopic observation. A) The similar cellular toxicity of 
extract was obtained by CV assay (CC50= 33.6±1.4%) and WST-1 assay (CC50=34.6±8%).; B) 
The similar anti-influenza activity of extract was observed between CV assay (IC50=1.6±0.2%) 
and WST-1 assay (IC50=1.4±0.0%); C) The cell morphology after 3 days incubation in the 
presence of extract with or without addition MOI of 0.002 of A/WSN/33; D) Oseltamivir activity 
against MOI of 0.002 of A/WSN/33 infection was evaluated using CV staining. The CC50 were 
calculated using linear regression of excel software, error bar was calculated from 2 independent 
experiments each done in triplicate, picture was taken using 6-well plate at 100 times 
magnification.     
 
To determine inhibitory potency of green A.linearis alkaline extract against 
influenza virus, the extract was challenged with increasing virus inocula infection of MOI 
of 0.001, MOI of 0.1, and MOI of 10 (Figure 13). As shown in Figure 13A, the dose 
dependent activity was observed until MOI of 10, with IC50 value 1.4±0.8%, 2.7±1.4%, 
and 5.9±5% for MOI of 0.001, 0.1, and 10, respectively. In addition, to confirm the extract 
potency against different MOI infection, we also evaluated the virus yield of culture 
supernatant using HA assay. HA assay detect the presence of virus HA protein. The HA 
assay of culture supernatant collected at day 3 post incubation of extract with A/WSN/33, 
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could not detect the HA protein at concentration of 1.25% for MOI of 0.001, 2.5% for 
MOI of 0.1, and 5% for MOI 1 (Figure 13B). These results suggest that alkaline extract 


















Figure 13. Dose dependent activity of green A. linearis alkaline extract against different MOI 
infection. A) The relative cell viability represented as relative OD value (%) is calculated after 3 
days incubation of cell and extract in the presence of different MOI infection; B) The HA assay 
result of culture supernatant collected at day 3 post incubation of extract and different MOI 
infection. The closed black square indicate infection of MDCK with MOI of 0.001, the closed 
gray square indicate infection of MDCK cells with MOI of 0.1, the open square indicate infection 
of MDCK cells with MOI of 10. 
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3.4   Activity of green A. linearis alkaline extract against human 
influenza virus type A and B 
In order to determine green A. linearis alkaline extract spectrum activity, we 
further evaluated its inhibitory effect against different types of human influenza viruses. 
For this purpose, a set of laboratory-adapted influenza viruses (A/PR/8/34, 
B/Brisbane/60/2008, B/Lee/40) and clinical isolates (A/Nagasaki/HA-58/2009, 
A/Nagasaki/HA-16/2009, A/Nagasaki/ HA-33/2009, A/Nagasaki/HA-58/2009 
Oseltamivir resistant, B/Okinawa/6/2014, B/Okinawa/7/2014 Oseltamivir-resistant, 
B/Okinawa/8/2014) were examined. The experiments showed that green A. linearis 
alkaline extract was effective against all influenza A and B viruses tested, even though its 
IC50 value against IBV was about two-fold higher than against IAV (Table 5). The extract 
also showed activity against all clinical isolates of influenza virus including oseltamivir-
resistant virus. 
 
In the current study, the alkaline extract of green A. linearis showed an inhibitory 
effect against three clinical isolates which had previously proved resistant to oseltamivir: 
A/Nagasaki/HA-58/2009 2009 pandemic virus which harbors the H257Y mutation in the 
NA glycoprotein (Kawano et al., 2011), B/Okinawa/4/2009 and B/Okinawa/7/2009 
(Charyasriwong et al., 2015; Charyasriwong et al., 2016). The ability of extract to inhibit 
different type of influenza virus and inhibit oseltamivir-resistant virus is suggestive 
evidence that A. linearis had a broad spectrum antiviral activity and would be potential 




Table 5. Activity of green A. linearis alkaline extract against different types of human 
influenza viruses. 






(%)   SI
a
 IC50 (µM ) SI 
Oseltamivir- 
sensitive 
A/Nagasaki/HA-6/2009    CI
c
 0.3 ± 0.0  134.6      36 ± 28   51.4 
A/Nagasaki/HA-33/2009  CI 1.2 ± 0.6    32.4      39 ± 16   47.4 
A/PR/8/34                          LS
d
 0.5 ± 0.1  102.9       9.4± 0.9  190 
A/WSN/33                        LS 1.6 ± 0.2    21.9       2.5± 0.5  740 
B/Brisbane/60/2008            LS 3.2 ± 0.0    13.5      75 ± 48   24.7 
B/Okinawa/6/2014             CI 3.0 ± 1.2    16.7      33 ± 6.5   56.1 
B/Okinawa/8/2014             CI 4.7 ± 0.8    12.8      11   67.3 
B/Lee/40                            LS 3.1 ± 0.3    17.3      23 ± 3.5   80.4 
Oseltamivir-
resistant 
A/Nagasaki/HA-58/2009  CI 0.9 ± 0.0    43.8    870    2.1 
B/Okinawa/4/2014            CI 3.8 ± 0.7   12.4    970    1.9 
B/Okinawa/7/2014            CI 3.2 ± 0.5    14.5 > 1000  < 1.8 
aSI was calculated as ratio of CC50 =34.6±8.0% which calculated by WST-1 assay, to each IC50 
value; boseltamivir IC50 value and SI was taken from Charyasriwong et al., 2016; cCI is 
abbreviation of clinical isolate; dLS is abbreviation of Laboratory strain. All data are represented 










3.5   Mode of action of green A. linearis alkaline extract 
To characterize the point within the influenza virus infection cycle which is 
inhibited by green A. linearis alkaline extract, we performed time course addition study, 
as reported previously (Wu et al., 2015; Makau et al., 2013) with some modifications. A 
single replication cycle of influenza virus was about 12 hours (h) and consists of four 
steps: virus entry (0-3h), viral genome replication and transcription (3-6 h), protein 
synthesis (6-9 h), and new virus assembly and release (9-12 h). In the present study, time 
course addition was performed at before infection, including cell and virus pretreatment, 
during and after infection of A/WSN/33 at MOI of 0.001 as depicted at Figure 14. 
 
The virus yield of each treatment was then compared to untreated control 
(without addition of extract or oseltamivir). Treatment of 5% green A. linearis alkaline 
extract with initial infection of MOI of 0.001, showed significant reduction of virus yield 
(p<0.05) at virus pretreatment, treatment during infection, with major reduction at 
treatment after infection (Figure 15A). These results may indicate that the extract not only 
interfering late stage of infection but also probably possess virucidal activity and/or 
inhibit virus entry, resulting in suppression of virus replication. In parallel as a control, 
20 µM oseltamivir treatment with initial infection of MOI of 0.001 showed significant 






Figure 14. Scheme of time-of-addition assay. Time-of-addition assay used to identify the 
inhibition steps of the influenza A virus life cycle by green A. linearis alkaline extract. A 5% of 
extract (green A. linearis alkaline extract) or 20 µM of oseltamivir was added into infected MDCK 
cells before, during and after infection or at different time points after infection. 
 
We further evaluated the green A. linearis alkaline extract activity at different 
time course after infection against MOI of 0.001 as shown in Figure 15. The significant 
virus yield reduction (p<0.05) in the presence of extract was observed at 6-9 h and higher 
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reduction was observed at 9-12 h treatment after infection as shown in Figure 15B. As a 
control, 20 µM oseltamivir showed significant virus yield reduction (p<0.05) at 9-12 h 













Figure 15. The virus yield of different time-of-addition assay experiment. Twelve hours after 
infection, supernatant from different time points treatment after infection of 5% extract (green A. 
linearis alkaline extract) or 20 µM oseltamivir treatment were collected and subjected to viral 
titration using the 50 % tissue culture infectious dose assay. The viral titer was then calculated 
using the Reed-Muench method. A) At initial MOI of 0.001 infection, 5% of the extract was able 
to reduce the virus yield at virus pretreatment, treatment during and after infection. In parallel, 20 
µM oseltamivir showed reduction of virus yield at treatment after infection against MOI of 0.001; 
B) Addition of 5% of the extract at different time point after infection with MOI of 0.001 showed 
that the extract significantly reduced virus yield at 6-9 h and mainly at 9-12 h treatment after 
infection. 20 µM Oseltamivir significantly reduced virus yield at 9-12 h treatment after infection. 
*The asterisks indicate the significant difference between control (untreated cells) and different 
time course treatment, p<0.05.  
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As the significant virus yield reduction was also observed at virus pre-treatment 
and treatment during infection at MOI of 0.001, we hypothesized that extract may exhibit 
weak virucidal activity or directly blocks the influenza HA particle to bind to cell receptor. 
In order to evaluate our speculation, we performed virus reduction assay and HI assay as 
described in material and methodology section. However, direct incubation of 
approximately about 1 × 106 TCID50/ml of A/WSN/33 with equal volume of green A. 
linearis alkaline extract at different concentrations at 37°C for 1 h could not reduce the 
virus titer as shown in Figure 16A. This result suggests that the extract does not possess 
virucidal activity. Furthermore, the HI assay showed no binding inhibition of HA protein 
to cell receptor as shown in Figure 16B. These results indicated that alkaline extract of 
green A. linearis exert its antiviral activity at late stages of viral life cycle either assembly 



























Figure 16. Virucidal and hemagglutination inhibition assay of green A. linearis alkaline extract. 
Its shown that green A. linearis alkaline extract do not possess virucidal activity or inhibit HA 
particles bind to cell receptor. A) Virucidal assay was performed by incubating equal volume of 
extract with A/WSN/33 at 37°C for 1 h. The mixture then subjected to virus titration by 50% 
tissue culture infection dose as explain in material and methodology section. The error bar value 
was calculated from two independent experiments; B) The HI assay was performed as described 






3.6   Storage stability and molecular weight of green A. linearis 
alkaline extract active constituent(s) 
To determine the properties of active ingredient(s) present in the green A. linearis 
alkaline extract, we evaluated its stability after storage. The cellular and anti-influenza 
activity of extract was evaluated after storage at -30°C for 1 day, 1 month, and 4 months 
storage at -30°C. It was observed that the extract still showed anti-influenza activity at 
similar level, even after 4 months storage. However, cellular toxicity of extract was 
gradually increased with prolonged in time of storage as shown in Figure 17A. The 
increase in cellular toxicity may result from extract component(s) other than its active 
component(s). In addition, molecular weight of active constituents of extract was 
determined by size exclusion filtration. Filtrates recovered from 100-, 50- and 10-kDa 
ultra filtration column were tested for its anti-influenza effects. The activity was observed 
at 100- and 50-kDa filtrate, whereas 10-kDa filtrate did not show any activity (Figure 
17B). The less potent activity of 100- and 50-kDa compared to crude extract can be 
explained by the fact that molecular weight close to nominal limit of molecular weight of 
column may be partially retained thus reducing its activity. These results indicate that the 








Figure 17. Storage duration and molecular size characterization. A) The storage duration at -30°C 
for 4 months did not decrease anti-influenza activity of green A. linearis alkaline extract. However, 
the storage at -30°C for more than a month cause increasing of cellular toxicity; B) The molecular 




CHAPTER 4: DISCUSION AND CONCLUSION 
 
In the present study, anti-influenza activity of green and red A. linearis leaves, 
A. nilotica pods and dried-hot water extract of U. gambir was evaluated. Among tested 
extracts, we found that green A.linearis alkaline extract showed high SI value and broad 
spectrum activity against influenza virus type A and B, including against oseltamivir-
resistant virus. Furthermore, analysis of virus infection step inhibited by the extract using 
time-of-addition assay suggested that the extract could interfere with late stages of 
influenza virus replication. This study is the first report showing that green A. linearis 
extract exhibit anti-influenza activity. 
 
Anti-influenza virus activity of A. linearis, A. nilotica and U. gambir was 
investigated by screening extracts, prepared by hot water, 1% sodium bicarbonate 
(alkaline) solution, 70% ethanol (ethanol), ethyl-acetate and n-hexane. Alkaline 
extraction method is more efficient in extracting the natural resources compounds, in 
particular polysaccharide, and effective in reducing the side effect when compared to hot 
water extract (Sakagami et al., 2013; Fiserova et al., 2012; Huang et al., 2010). Meanwhile 
as the target active compound(s) may range from polar to nonpolar, ethanol, ethyl acetate 
and n-hexane solvents were used to extract the compounds with different polarity.  
 
All tested extracts showed inhibition against influenza virus infection. Hot water, 
alkaline and ethanol extracts of A. nilotica and U. gambir showed lowest IC50 value, 
indicating that these extracts pose strongest anti-influenza activity among all tested 
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extracts. Indeed, A. nilotica had been reported to inhibit other unrelated virus including 
HIV-1 virus, hepatitis C virus, and herpes simplex virus (Sharma et al., 2014; Nutan et 
al., 2013; Rehman et al., 2011). Together with our recent results, it indicates that A. 
nilotica possess broad antiviral activity against different viruses. Our study also 
demonstrated for the first time that U. gambir can be developed to be a potential anti-
influenza candidate. 
 
Drug safety is a major concern in the development of new drugs. Thus, the 
minimal cellular toxicity might serve as good criteria for selecting potential candidates 
for the development of safe and less toxic drug (Rajasekaran et al., 2013). In the present 
study, green A. linearis extracted by alkaline solution showed high IC50 value but less 
cellular toxicity when compared to other plants extract tested, resulting in a highest SI 
value as shown in Table 4. Further evaluation by WST-1 assay and phase-contrast 
microscopic revealed that SI value of green A. linearis alkaline extract is 21.9. Thus, 
green A. linearis alkaline extract seems to be a good candidate for anti-influenza drug 
development. Previous study reported that crude extract of alkaline solution of A. linearis 
posed activity against HIV-1 (Nakano et al., 1997). Together with our current result, it is 
evident that alkaline extract of A. linearis might has broad anti- viral activity especially 
against RNA viruses. In the recent past, emerging RNA viruses have caused sporadic 
outbreaks in various parts of the world with pandemic potential such as Ebola outbreak 
in 2014 and Zika virus outbreak in 2015. The ability of A. linearis to inhibit replication 
of RNA viruses and global consumption of A. linearis as herbal tea highlights its potential 
83 
 
application in control and management of viral pandemics. It will be interesting to further 
investigate the effect of A. linearis against emerging RNA viruses. 
 
 Influenza type A and B viruses are responsible for severe morbidity and 
mortality worldwide during annual epidemics (Houser et al., 2015; Palese and shaw, 
2007; Taubenberger and Morens, 2008). In addition, emergence of oseltamivir-resistant 
virus has been spread worldwide, cause main concern worldwide (Ciancio et al., 2009; 
Mckimm-Breschkin, 2012; Van der Vries, 2010; Rousset et al., 2010). The development 
of new NA inhibitors, laninamivir, peramivir and RNA polymerase inhibitor, favipiravir 
is helping to curb further spread of oseltamivir-resistant virus. However, the use of 
laninamivir and favipiravir are only available in Japan and to note, laninamivir and 
peramivir are also associated with unfavorable pharmacokinetics and must administered 
through inhalation (laninamivir, zanamivir) or intravenously (peramivir) (Shen et al., 
2015). In addition, zanamivir and laninamivir are still possible to develop the resistant 
mutant as reported by McKimm -Breschkin, 2012 and Yen et al., 2006. Thus, in present 
study we also evaluated green A. linearis extract against influenza type A and B including 
clinical isolate of oseltamivir-resistant virus. As shown in Table 5, green A. linearis 
alkaline extract inhibit different types of influenza viruses and interestingly also effective 
against clinical isolates of oseltamivir-resistant influenza virus A/Nagasaki/58/2009 
pandemic 2009 which contain mutation at H257Y of NA glycoprotein (Kawano et al., 
2011) and oseltamivir- resistant influenza virus B/Okinawa/4 and B/Okinawa/7 
(Charyasriwong et al., 2016). The green A. linearis alkaline extract ability to inhibit 
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oseltamivir-resistant virus suggest that A. linearis can be a potential source for 
development of new anti-influenza therapeutic.   
 
As shown in Figure 15, time-of-addition assay results indicated that inhibitory 
effect of green A. linearis alkaline extract exert its activity mainly at late stage of infection. 
Significant virus reduction at virus pretreatment and during infection were also observed. 
However, the extract did not show virucidal activity or entry-inhibitory activity in 
blocking virus particle to bind to sialic acid (Figure 16). Previous study using different 
plant extracts, reported the similar result and suggested that these phenomena related to 
neuraminidase inhibition activity. (Rajasekaran et al., 2013; Hsieh et al., 2012). The 
cleavage of sialic acid and HA linkage by nerauminidase (NA) is one of the steps in late 
stages of virus infection. This enzymatic cleavage is important for virus release, spread 
and entry to the cells (Matrosovich et al., 2004; Su et al., 2009). NA also has function to 
mask the glycoconjugate, expressed in the surface of host cell, thus enable binding of HA 
particles to host cell. In addition, desialylation of HA by sialidase could removes the acid 
sialic residue of HA protein which will partially unmasking the HA protein and facilitate 
its binding to target cell surface. Thus, the inhibition of NA activity will lead to inhibition 
of virus entry. The facts that green A. linearis alkaline extract interfere mainly at late stage 
infection and significantly reduced virus yield at virus pretreatment and during infection 
without virucidal activity and HA inhibitory activity, suggests that some component(s) of 
extract may possess sialidase inhibition activity. In addition, the extract inhibition at late 
stage of infection together with anti-influenza activity against oseltamivir-resistant virus 
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lead us to speculate that the extract active component(s) target different site from 
oseltamivir.  
 
The increase in cellular toxicity of green A.linearis alkaline extract without 
reduction in antiviral activity after more than one month storage is probably caused by 
other unstable component(s) present in the extract other than its active component(s).  
Although the active constituent(s) molecular weight in the present study is more than 10 
kDa as shown in Figure 17B, the active constituent of the alkaline extract of A. linearis, 
which is responsible for antiviral activity, is presently unknown. Since anti-influenza 
virus activity could only be observed in ethanol, hot water and alkaline extracts as shown 
in Table 4, the polyphenolic content present in the alkaline extract could represent as a 
promising candidate as active component(s) (Joubert and de Beer, 2012; Nencioni et al., 
2003; Ciriolo et al., 1997; Marnewick et al., 2003).  
 
The phenolic compound(s) may present as a free state or conjugated with sugar 
or ester or polymerized (Mujica et al., 2009). In addition, the alkaline extract using similar 
method as used in our study has been demonstrated to have the ability to extract the alkali-
soluble crude polysaccharide (Huang et al., 2010; Fiserova and Opalena, 2012). A 
Previous study which examined the antiviral activity of green A. linearis alkaline extract 
against HIV-1 infection, concluded that the active component of A. linearis extract, in 
this particular instance, was polysaccharide (Nakano et al., 1997). In addition, Nakano et 
al. also mentioned that the purified polysaccharide from alkaline extract of A. linearis 
contains about 15.4-24.9% of uronic acid. Uronic acid was reported by Mann et al., 2006, 
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to be effective in inhibiting influenza sialidase in vitro neuraminidase assay. Thus, the 
possibility of uronic acid contain in A.linearis as main active component against influenza 
virus cannot be excluded. 
 
To note, A. Linearis is a famous health beverage in Africa, Europe and Japan. 
The absence of alkaloids especially caffeine and rich of mineral contents such as iron, 
calcium, magnesium, zinc, copper and potassium are believed to give positive benefit to 
the body (Joubert et al., 2008). In South Africa, it is traditionally used in curing infant 
colic, improving appetite, alleviating dermatological problem and relieving stress. 
Scientific research has revealed its anti-mutagenic, antioxidant, and antiviral activity. Our 
result showed that A. linearis exhibit activity against different types of influenza virus 
including oseltamivir-resistant clinical isolate of the 2009 pandemic flu. These results 
suggest that eventhough further studies are required to characterize its active components, 
the daily consumption of A. linearis as herbal tea can be useful as prophylactic treatment 
against influenza virus infections and may be applicable for management for future 
pandemic virus. 
 
 In conclusion, all plant extracts tested exhibit anti-influenza activity, in 
particular green A. linearis alkaline extract. The green A. linearis alkaline extract has 
potent inhibitory effects against the influenza virus and effective to inhibit clinical isolate 
of pandemic 2009 oseltamivir-resistant virus strains. The green A. linearis alkaline extract 
exert it antiviral activity predominantly at late stage of infection. Further studies are now 
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